Search clinical trials for: BOOSTRIX

Total 76 results

GlaxoSmithKline

Completed

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

Tetanus | Diphtheria | Acellular Pertussis

Belgium
St. Justine's Hospital
Ministere de la Sante et des Services Sociaux

Completed

Pertussis Vaccination in Pregnant Women

Pertussis

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

Tetanus | Diphtheria | Acellular Pertussis

Mexico, Chile
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

Diphtheria-Tetanus-acellular Pertussis Vaccines

Russian Federation
GlaxoSmithKline

Completed

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

Respiratory Syncytial Virus Infections

United States, Belgium, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines

Australia
University of Prince Edward Island
The Queen Elizabeth Hospital

Completed

The Feasibility of Pertussis Immunization in a Canadian Emergency Department

Pertussis

Canada
St George's, University of London
European Society for Paediatric Infectious Diseases

Unknown

Maternal Antibody in Milk After Vaccination (MAMA)

Pertussis | Pregnancy | Vaccination | Breastmilk

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis

Germany
Norwegian Institute of Public Health

Completed

Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine

Pertussis | Tetanus | Diphtheria | Polio

Norway
Green Cross Corporation

Unknown

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Whooping Cough | Tetanus | Diphtheria

Korea, Republic of
GlaxoSmithKline

Completed

Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children

Tetanus | Diphtheria | Acellular Pertussis

Vietnam
University Hospital, Ghent
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; Novartis Vaccines; University... and other collaborators

Completed

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Prevention of Infections With Bordetella Pertussis

Belgium
GlaxoSmithKline

Terminated

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Tetanus | Diphtheria | Acellular Pertussis

Australia
Emory University
Universidad del Valle, Guatemala

Completed

Maternal Tdap Immunization in Guatemala

Pertussis | Whooping Cough

Guatemala
GlaxoSmithKline

Completed

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Tetanus | Diphtheria | Acellular Pertussis

United States
London School of Hygiene and Tropical Medicine
Radboud University Medical Center; University of Turku; Imperial College London; University of Oxford and other collaborators

Active, not recruiting

Gambia Pertussis Study (GaPs) (GaPs)

Pertussis

Gambia
Green Cross Corporation

Unknown

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

Whooping Cough | Tetanus | Diphtheria

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women

Diphtheria-Tetanus-acellular Pertussis Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

Tetanus | Diphtheria | Acellular Pertussis

China
GlaxoSmithKline

Completed

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Respiratory Syncytial Virus Infections

Belgium
University of Oxford
University of Turku; National Institute for Public Health and the Environment...

Completed

A Study Exploring Whooping Cough Protection in Children and Adults (BERT)

Pertussis

United Kingdom, Finland, Netherlands
ILiAD Biotechnologies

Active, not recruiting

Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Bordetella Pertussis, Whooping Cough

United Kingdom, Australia, Costa Rica
GlaxoSmithKline

Completed

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Tetanus | Diphtheria | Acellular Pertussis

United States
Sanofi

Completed

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

Pertussis | Tetanus | Diphtheria

United States
GlaxoSmithKline

Completed

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Herpes Zoster

United States
GlaxoSmithKline
Kaiser Permanente

Completed

The Safety of Boostrix Following Routine Immunization of Pregnant Women

Whooping Cough

United States
Universiteit Antwerpen
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Pertussis (Tdap) Vaccination in Pregnancy

Pertussis | Pregnancy

Belgium, Vietnam
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Infections, Meningococcal

Germany, Korea, Republic of, Dominican Republic
Novartis

Completed

Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)

Pertussis

Belgium
Siegrist Claire-Anne
BioNet-Asia Co., Ltd.

Completed

The PertADO Geneva Trial

Pertussis

Switzerland
Boehringer Ingelheim

Completed

Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females

Healthy
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Tetanus | Diphtheria | Acellular Pertussis

Finland
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Infections, Papillomavirus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

Pertussis | Whooping Cough | Tetanus | Diphtheria

United States
DBV Technologies
University Hospital, Geneva

Completed

Viaskin Pertussis Vaccine Trial

Whooping Cough

Switzerland
Public Health England
Institute of Child Health; St George's, University of London

Completed

A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants (iMAP2)

Responses to Infant Immunisations

United Kingdom
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
GlaxoSmithKline

Completed

Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis

France, Germany
GlaxoSmithKline

Completed

Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

Diphtheria-Tetanus-acellular Pertussis Vaccines

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

Tetanus | Diphtheria | Acellular Pertussis

Spain, Netherlands, Belgium

3

Subscribe